Not so benign: Life-threatening hematuria from renal papillary necrosis in sickle cell trait Authors: Katharine Hodgen, Parth Joshi, Megan Ngai, Jeffrey Schiff Published: 2026 ABSTRACT Renal papillary necrosis (RPN) is an uncommon but important cause of hematuria in patients with sickle cell trait. We report a 28-year-old female with sickle cell trait and beta thalassemia who developed recurrent, transfusion-dependent gross hematuria. Despite extensive imaging, endoscopic evaluation, and conservative management, bleeding persisted. Ureteroscopy demonstrated findings consistent with RPN. The patient required intensive multidisciplinary care and 21 units of packed red blood cells. Hematuria ultimately resolved following treatment with oral epsilon-aminocaproic acid. This case highlights the potential severity of RPN in sickle cell trait and supports consideration of antifibrinolytics as salvage therapy in refractory cases. Introduction Renal papillary necrosis (RPN) is a pathological condition characterized by ischemic injury to the renal medullary pyramids and papillae, often resulting from microvascular compromise in the renal medulla. It is associated with a variety of systemic and local risk factors, including diabetes mellitus, analgesic use, urinary tract infections, obstructive uropathy, renal tuberculosis and hemoglobinopathies such as sickle cell disease and trait.1 While sickle cell trait is often considered a benign carrier state, it is increasingly recognized as a potential cause of clinically significant renal complications due to episodic sickling of red blood cells in the hypoxic, hyperosmolar, and acidic environment of the renal medulla, leading to microvascular occlusion and papillary ischemia.2,3 Hematuria is one of the most common renal manifestations of sickle cell trait, typically self-limited, but in rare cases it may be severe, recurrent, and even life-threatening.4,5 Renal papillary necrosis is the suspected underlying pathology in many such cases, although the diagnosis can be challenging. Imaging such as CT urogram or MR urogram may show indirect signs of papillary necrosis, but definitive diagnosis may require ureteroscopic visualization. Treatment is often conservative, involving hydration and urine alkalinization, but refractory cases may necessitate antifibrinolytic therapy, interventional radiology procedures or surgical interventions.6 There is limited literature guiding the management of severe hematuria due to RPN in patients with sickle cell trait. Some reports have described successful use of desmopressin (DDAVP) and antifibrinolytic agents such as tranexamic acid (TXA) or epsilon-aminocaproic acid (Amicar) in controlling persistent hematuria 7, 8, 9, 10. However, the use of antifibrinolytics in this context is controversial due to the potential risk of thrombosis and obstructive clots, especially in patients with a concurrent hypercoagulable state or a history of deep vein thrombosis. We present a rare and clinically complex case of a 28-year-old female with beta thalassemia and sickle cell trait who developed recurrent, transfusion-dependent gross hematuria due to renal papillary necrosis. This case is notable for the severity of bleeding, need for multidisciplinary management including urology, nephrology, hematology and critical care, and eventual successful treatment with oral Amicar after failure of conservative therapy. The purpose of this case report is to illustrate the potential for severe renal complications in sickle cell trait, highlight diagnostic and therapeutic challenges in identifying and managing renal papillary necrosis, and contribute to the limited literature on the use of antifibrinolytic therapy in hematuria associated with sickle cell trait. Case This case report describes a 28-year-old female with a history of beta thalassemia and sickle cell trait who presented with recurrent gross hematuria. Her initial episode occurred at age 19 in 2015 and required transfusion of two units of packed red blood cells. A second episode in 2022 resolved spontaneously after three days. She re-presented to the emergency room in January 2024 with gross hematuria associated with flank pain and nausea. Initial urinalysis demonstrated >100 red blood cells per high-power field (RBC/HPF) and 51–100 white blood cells per high-power field (WBC/HPF), and she was treated empirically for a urinary tract infection. She reported occasional alcohol, hookah, and NSAID use, without history of smoking, nephrolithiasis, recurrent urinary tract infections, or relevant family history. She was subsequently referred to a general urologist, in which repeat evaluation demonstrated persistent hematuria with negative urine culture. A computed tomography (CT) urogram revealed mild bilateral calyceal blunting and irregularity, with contrast collections in the papillary regions and streak-like densities suggestive of RPN. There were small, sub centimeter cortical cysts in the upper pole of right kidney. No hydronephrosis, nephrolithiasis, or filling defects were identified. Cystoscopy showed a normal urethra and bladder without lesions or masses. Nephrology evaluation revealed stage 1 chronic kidney disease with preserved renal function. Glomerular serologic workup and antiphospholipid testing were negative. Given her history of sickle cell trait and medullary cysts on imaging, magnetic resonance (MR) urogram was obtained to exclude medullary renal carcinoma; this demonstrated symmetric renal enhancement without masses and stable calyceal abnormalities. Diagnostic ureteroscopy was then recommended to evaluate for possible arteriovenous malformations (AVMs). On March 7, 2024, the patient underwent cystoscopy, bilateral retrograde pyelograms, attempted ureteroscopy, and bilateral ureteral stent placement. Retrograde studies demonstrated bilaterally narrowed ureters without hydronephrosis. Due to resistance preventing advancement of the ureteroscope, bilateral 6F × 26 cm ureteral stents were placed for passive dilation. She returned for planned ureteroscopy on March 26, 2024, but was found to be febrile to 104.9 °F and was admitted with septic shock requiring vasopressors. Blood and urine cultures grew Group B Streptococcus. Imaging raised concern for bilateral renal abscesses, which resolved with intravenous antibiotics. She was discharged on oral antibiotics with ureteral stents in place. Definitive ureteroscopy was performed on April 11, 2024. Left-sided pyeloscopy revealed a small area of venous congestion in the midpole without active bleeding (Fig. 1). On the right, a similar lesion in the upper pole demonstrated bleeding with instrumentation that resolved spontaneously. No AVMs or other abnormalities were identified, and findings were consistent with RPN. The ureters were normal bilaterally. At follow-up, the patient was asymptomatic without hematuria.Fig. 1Pyeloscopy of left kidney showing venous congestion in midpole.Fig. 1 Pyeloscopy of left kidney showing venous congestion in midpole. Three months later, in July 2024, she presented with five days of gross hematuria with clot passage and difficulty voiding, followed by right flank pain, dysuria, dizziness, and weakness. Laboratory evaluation revealed hemoglobin of 6.6 g/dL (decreased from 9.3 g/dL). Urinalysis demonstrated significant hematuria, pyuria, and bacteriuria. CT urogram showed a blood clot in the right renal pelvis without hydronephrosis or evidence of pyelonephritis (Fig. 2). Initial management included empiric antibiotics, bladder monitoring with intermittent catheterization, bedrest, and nephrology-directed supportive care. Recommendations included aggressive intravenous hydration, maintenance of hemoglobin above 7 g/dL, avoidance of nephrotoxins, and close monitoring of renal function, which remained at baseline. CT angiography demonstrated no active bleeding, and interventional radiology deferred embolization.Fig. 2CT Urogram showing blood products in right renal pelvis.Fig. 2 CT Urogram showing blood products in right renal pelvis. Despite conservative management, the patient continued to experience persistent hematuria with clot passage requiring multiple transfusions. Cultures remained negative. Multidisciplinary management with nephrology and hematology included urine alkalinization with sodium bicarbonate infusion and intravenous iron supplementation. Laboratory evaluation showed normal von Willebrand factor activity. Due to ongoing bleeding and anemia, repeat renal arteriography was performed on July 22, 2024 and again demonstrated no active hemorrhage. The patient developed clot retention requiring placement of a 20F three-way Foley catheter and continuous bladder irrigation, with intermittent manual irrigation and catheter exchanges. A left upper extremity deep vein thrombosis, likely midline catheter-associated, was identified; anticoagulation was deferred due to active bleeding. Given persistent transfusion requirements and refractory hematuria, the patient was started on oral Amicar on July 30, 2024 at a dose of 2500 mg three times daily. This resulted in significant clinical improvement, with resolution of hematuria and yellow urine by day six of treatment. Dose reduction led to recurrence of hematuria, necessitating temporary dose escalation, followed by gradual tapering over one week. Concurrent sodium bicarbonate infusion was tapered and discontinued after correction of acid-base status. The patient was discharged with complete resolution of hematuria and no further transfusion requirements. During this admission, she received a total of 21 units of packed red blood cells. She was discharged with close outpatient follow-up with urology, nephrology, and hematology. Discussion This case describes a rare and complex presentation of recurrent gross hematuria due to RPN in a young patient with beta thalassemia and sickle cell trait which resulted in significant morbidity. This includes endoscopic procedures, urosepsis, transfusion-dependent anemia, urinary retention, and prolonged hospitalization requiring multidisciplinary care. Although sickle cell trait is often considered benign, it can cause symptomatic hematuria through microvascular ischemia and papillary sloughing, particularly under hypoxic, hyperosmolar, or acidic renal medullary conditions.11,12 While RPN in sickle cell trait has been described, severe recurrent bleeding requiring 21 units of packed red blood cells and prolonged hospitalization is uncommon. Despite extensive imaging, endoscopic evaluation and renal arteriography, no discrete bleeding source was identified. Ureteroscopic findings of venous congestion and papillary changes were most consistent with RPN. Amicar proved effective when conservative measures failed. Although antifibrinolytics are typically avoided in sickle cell trait due to thrombosis risk, careful monitoring allowed for safe administration in this case despite concurrent upper extremity DVT. Prior reports describe use of antifibrinolytics and DDAVP in refractory hematuria. Studies have demonstrated that Amicar can shorten duration of hematuria without significantly increasing thrombosis risk, while DDAVP has shown variable efficacy, with some patients responding rapidly and others requiring repeated dosing or failing therapy 4,6, 7, 8,11,13. If medical management fails, escalation to renal artery embolization or nephrectomy may be required. Conservative strategies, including transfusion, hydration, and urine alkalinization, have shown benefit in some cases.4,11 This case highlights the importance of a multidisciplinary approach involving urology, nephrology, hematology, and interventional radiology in managing complex, transfusion-dependent hematuria. This case has several clinical implications. First, sickle cell trait should not be considered entirely benign, as it can result in significant complications such as RPN and severe hematuria, particularly with coexisting conditions like beta thalassemia. Second, stepwise management from supportive care to invasive diagnostics and antifibrinolytics is critical in refractory cases. Third, antifibrinolytics may be considered when conservative measures fail and embolization is not feasible, with careful monitoring to mitigate risks. There is limited literature on the natural history and recurrence risk of RPN-associated hematuria in sickle cell trait, as well as on optimal treatment strategies using antifibrinolytics or DDAVP. Further studies are needed to better define risk stratification and guide management. Limitations include lack of histologic confirmation of RPN due to bleeding risk of biopsy, unclear contribution of beta thalassemia, and limited data on the safety of antifibrinolytics in this population. Additional contributing factors, such as NSAID use or subclinical urinary tract infections, were not fully characterized. Conclusion This case highlights a rare and severe manifestation of renal papillary necrosis due to sickle cell trait, resulting in recurrent, transfusion-requiring gross hematuria. Through a systematic diagnostic and therapeutic approach, including ureteroscopy, imaging, aggressive hydration, alkalinization of urine, bladder management, and ultimately the use of Amicar, the patient achieved resolution of bleeding. This case emphasizes the potential seriousness of sickle cell trait-related hematuria and supports the inclusion of antifibrinolytics as a salvage therapy with close clinical monitoring. CRediT authorship contribution statement Katharine Hodgen: Data curation, Investigation, Project administration, Writing – original draft, Writing – review & editing. Parth Joshi: Conceptualization, Data curation, Writing – review & editing. Megan Ngai: Data curation, Writing – original draft. Jeffrey Schiff: Supervision. Declaration of AI During the preparation of this work the author(s) used ChatGPT in order to brainstorm and summarize content. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.